Injectable PrEP drug holds promise but investment in HIV prevention has declined dramatically worldwide
New innovations in HIV prevention could dramatically reduce the number of new HIV cases around the globe, but US foreign aid cuts will mean that those that most need the new medication will be unable to access it, according to experts at the Aids 2026 Conference in Rio de Janeiro, Brazil.
One year ago, the World Health Organization recommended that governments around the world prioritize expanded access to lenacapavir, an injectable version of the HIV prevention medication PrEP that requires only two injections annually. PrEP, which also comes in the form of daily oral medications and bimonthly injections, is 99% effective in preventing sexually transmitted HIV for people who take it consistently.
Continue reading...This article was originally published by The Guardian and written by Hannah Harris Green in Rio de Janeiro.
Read original article on The Guardian